Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 141

Similar articles for PubMed (Select 23851329)

1.

PIK3CA mutations and PTEN loss in salivary duct carcinomas.

Griffith CC, Seethala RR, Luvison A, Miller M, Chiosea SI.

Am J Surg Pathol. 2013 Aug;37(8):1201-7. doi: 10.1097/PAS.0b013e3182880d5a.

PMID:
23851329
2.

PIK3CA, HRAS and PTEN in human papillomavirus positive oropharyngeal squamous cell carcinoma.

Chiosea SI, Grandis JR, Lui VW, Diergaarde B, Maxwell JH, Ferris RL, Kim SW, Luvison A, Miller M, Nikiforova MN.

BMC Cancer. 2013 Dec 17;13:602. doi: 10.1186/1471-2407-13-602.

3.

Oncogenic PIK3CA mutation and dysregulation in human salivary duct carcinoma.

Qiu W, Tong GX, Turk AT, Close LG, Caruana SM, Su GH.

Biomed Res Int. 2014;2014:810487. doi: 10.1155/2014/810487. Epub 2014 Jan 8.

4.

Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma.

Byun DS, Cho K, Ryu BK, Lee MG, Park JI, Chae KS, Kim HJ, Chi SG.

Int J Cancer. 2003 Apr 10;104(3):318-27.

PMID:
12569555
5.

PIK3CA mutations in advanced cancers: characteristics and outcomes.

Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, Fu S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA, Moulder SL, Lee JJ, Luthra R, Hong DS, Kurzrock R.

Oncotarget. 2012 Dec;3(12):1566-75.

6.

Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment.

Nardi V, Sadow PM, Juric D, Zhao D, Cosper AK, Bergethon K, Scialabba VL, Batten JM, Borger DR, Iafrate AJ, Heist RS, Lawrence DP, Flaherty KT, Bendell JC, Deschler D, Li Y, Wirth LJ, Dias-Santagata D.

Clin Cancer Res. 2013 Jan 15;19(2):480-90. doi: 10.1158/1078-0432.CCR-12-1842. Epub 2012 Nov 27.

7.

An analysis of PLAG1 and HMGA2 rearrangements in salivary duct carcinoma and examination of the role of precursor lesions.

Bahrami A, Perez-Ordonez B, Dalton JD, Weinreb I.

Histopathology. 2013 Aug;63(2):250-62. doi: 10.1111/his.12152. Epub 2013 Jun 6.

PMID:
23738717
8.

Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas.

Murugan AK, Hong NT, Fukui Y, Munirajan AK, Tsuchida N.

Int J Oncol. 2008 Jan;32(1):101-11.

PMID:
18097548
9.

PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations.

Velasco A, Bussaglia E, Pallares J, Dolcet X, Llobet D, Encinas M, Llecha N, Palacios J, Prat J, Matias-Guiu X.

Hum Pathol. 2006 Nov;37(11):1465-72. Epub 2006 Jul 26.

PMID:
16949921
10.

EGFR, PIK3CA and PTEN gene status and their protein product expression in neuroblastic tumours.

Izycka-Swieszewska E, Brzeskwiniewicz M, Wozniak A, Drozynska E, Grajkowska W, Perek D, Balcerska A, Klepacka T, Limon J.

Folia Neuropathol. 2010;48(4):238-45.

PMID:
21225506
11.

Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.

Razis E, Bobos M, Kotoula V, Eleftheraki AG, Kalofonos HP, Pavlakis K, Papakostas P, Aravantinos G, Rigakos G, Efstratiou I, Petraki K, Bafaloukos D, Kostopoulos I, Pectasides D, Kalogeras KT, Skarlos D, Fountzilas G.

Breast Cancer Res Treat. 2011 Jul;128(2):447-56. doi: 10.1007/s10549-011-1572-5. Epub 2011 May 19.

PMID:
21594665
12.

Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis.

Catasus L, Gallardo A, Cuatrecasas M, Prat J.

Mod Pathol. 2009 Apr;22(4):522-9. doi: 10.1038/modpathol.2009.5. Epub 2009 Feb 20.

13.

Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.

Ramirez-Ardila DE, Helmijr JC, Look MP, Lurkin I, Ruigrok-Ritstier K, van Laere S, Dirix L, Sweep FC, Span PN, Linn SC, Foekens JA, Sleijfer S, Berns EM, Jansen MP.

Breast Cancer Res Treat. 2013 May;139(1):39-49. doi: 10.1007/s10549-013-2529-7. Epub 2013 Apr 17.

PMID:
23592373
14.

Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients.

Schneck H, Blassl C, Meier-Stiegen F, Neves RP, Janni W, Fehm T, Neubauer H.

Mol Oncol. 2013 Oct;7(5):976-86. doi: 10.1016/j.molonc.2013.07.007. Epub 2013 Jul 13.

15.

Predictors of cervical lymph node metastasis in salivary gland cancer.

Ettl T, Gosau M, Brockhoff G, Schwarz-Furlan S, Agaimy A, Reichert TE, Rohrmeier C, Zenk J, Iro H.

Head Neck. 2014 Apr;36(4):517-23. doi: 10.1002/hed.23332. Epub 2013 Jun 18.

PMID:
23780687
16.

PIK3CA mutations in endometrial carcinomas in Chinese women: phosphatidylinositol 3'-kinase pathway alterations might be associated with favorable prognosis.

Dong Y, Yang X, Wong O, Zhang X, Liang Y, Zhang Y, Wong W, Nong L, Liao Q, Li T.

Hum Pathol. 2012 Aug;43(8):1197-205. doi: 10.1016/j.humpath.2011.08.021. Epub 2011 Dec 30.

PMID:
22209294
17.

PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.

Sood A, McClain D, Maitra R, Basu-Mallick A, Seetharam R, Kaubisch A, Rajdev L, Mariadason JM, Tanaka K, Goel S.

Clin Colorectal Cancer. 2012 Jun;11(2):143-50. doi: 10.1016/j.clcc.2011.12.001. Epub 2012 Jan 28.

18.

Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.

Ludovini V, Bianconi F, Pistola L, Chiari R, Minotti V, Colella R, Giuffrida D, Tofanetti FR, Siggillino A, Flacco A, Baldelli E, Iacono D, Mameli MG, Cavaliere A, Crinò L.

J Thorac Oncol. 2011 Apr;6(4):707-15. doi: 10.1097/JTO.0b013e31820a3a6b.

PMID:
21258250
19.

Molecular Characterization of Apocrine Salivary Duct Carcinoma.

Chiosea SI, Williams L, Griffith CC, Thompson LD, Weinreb I, Bauman JE, Luvison A, Roy S, Seethala RR, Nikiforova MN.

Am J Surg Pathol. 2015 Feb 26. [Epub ahead of print]

PMID:
25723113
20.

Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome.

Bettstetter M, Berezowska S, Keller G, Walch A, Feuchtinger A, Slotta-Huspenina J, Feith M, Drecoll E, Höfler H, Langer R.

Hum Pathol. 2013 May;44(5):829-36. doi: 10.1016/j.humpath.2012.08.005. Epub 2012 Nov 14.

PMID:
23158210
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk